Dashboard/AKRO/efruxifermin/event

InterimInterim Analysis

Efruxifermin SYMMETRY Phase 3 Interim (MASH)

AKRO·efruxifermin·MASH (NASH)·

Phase 3

·NCT04880421

current best date

'27

QTR8 months

Takeaway

Pre-specified Phase 3 interim for efruxifermin (FGF21 analog) in compensated cirrhotic MASH. REZDIFFRA (the only approved MASH drug) is not approved in cirrhotic patients. Watch: ≥1-stage fibrosis improvement without MASH worsening at week 36.

What’s at stake

market · comparables · base rate · prior moves

Market opportunity

—

company filings

Peer comparables

1 readout

ClinicalTrials.gov

Stage base rate

~58%

BIO Industry Analysis 2023 (2011–2020)

Avg prior-readout move

—

historical price reactions

MoAFGF21 analog Fc-fusion

Efruxifermin is a weekly subcutaneous Fc-fusion analog of fibroblast growth factor 21 (FGF21) — a liver-secreted hormone regulating fat metabolism, insulin sensitivity, and energy balance — developed by Akero Therapeutics for MASH. The Fc-fusion domain extends the half-life of FGF21 from minutes to a week, enabling once-weekly dosing. Akero is evaluating efruxifermin in Phase 3 trials in both pre-cirrhotic (F2/F3) and cirrhotic (F4) MASH; REZDIFFRA, the only approved MASH drug, was not studied in cirrhotic patients, leaving that population entirely without an approved option.

Indication

NASH / MASH

MASH (NASH)

MeSH · D065626

No primer in glossary yet.

Trial

active

NCT04880421 ↗

SYMMETRY Phase 3 Efruxifermin in pre-cirrhotic MASH

Glossary · what this readout is measuring

1 term detected in the takeaway

MASHdisease
Metabolic-Associated Steatohepatitis
Liver inflammation caused by fat accumulation, with metabolic risk factors. Renamed from NASH in 2023. Resmetirom (REZDIFFRA) is the only approved therapy.

Sector base rates · reference data

historical record · not prediction

of 3 historical Phase 3 readouts in NASH / MASH: 1 positive, 1 mixed, 1 negative.

Positive

1/ 3

33%

Mixed

1/ 3

33%

Negative

1/ 3

33%

positive rate 33% · primary endpoint hit rate 67%

Reference data · comparable readouts

How Ph3 readouts in NASH / MASH have landed.

Reference, not prediction. We surface the historical record so you can read it yourself. We never extrapolate to the upcoming event.

Positive

1/3

33% in record

Primary endpoint hit

67%

across 3 readouts

Drug · sponsorPhase · yearOutcomeKey metricSource

lanifibranor

INVE · NASH

Ph3 · Jul 2024mixedhit primary; long-term durability questioned8-K

aramchol

GLMD · NASH

Ph3 · Apr 2024negativefailed primary; histology unchanged8-K

resmetirom (MAESTRO-NASH)

MDGL · NASH

Ph3 · Dec 2023positiveNASH resolution 26% vs 9% pboPR

efruxifermin

AKRO · NASH

Ph2 · Sep 2024positiveF2-F3 fibrosis improvement 39%PR

pegozafermin

89bio · NASH

Ph2 · Jun 2023positivefibrosis improvement 26%conference

sorted by phase match, then recency · sources span PR wires, CT.gov, FDA notices, and conference presentations · we never editorialize the outcome label

Competitive landscape

1 peer in NASH / MASH · ranked by indication + modality match

Drug	Company	Modality	Mechanism	Phase	Next catalyst
REZDIFFRAresmetirom	MDGL	small molecule	thyroid hormone receptor-β agonist		INTERIM · Oct 26

Disclosure trail

1 observation · sorted by confidence

Apr 9, 2026·21d agopinned · highest confidence
MED confPR
top claim
Q1'27
QTR
“The pre-specified Phase 3 SYMMETRY interim analysis is expected in the first quarter of 2027.”
conf 83%via llm

MethodologyEvery catalyst date is anchored to a primary source. Disclosures with confidence ≥ 0.85 auto-publish; the rest are reviewed by a human within 24 hours. We never interpret data — we organize public information.